https://vitasmlab.net

INFLUMARK

Influenza Targeted Library

Influenza viruses cause seasonal epidemics and unpredictable pandemics, posing major global health threats. Their high mutation rate allows evasion of vaccines and immunity, while zoonotic jumps (e.g., avian/swine flu) risk deadly outbreaks. Current antivirals target viral neuraminidase or polymerase, but resistance is rising, and efficacy is often limited. Novel drugs are urgently needed to combat evolving strains, especially for high-risk groups. Promising targets include the conserved hemagglutinin stem, host dependency factors, and viral RNA synthesis machinery. Broad-spectrum therapies could prevent seasonal flu, mitigate pandemics, and reduce the hundreds of thousands annual deaths linked to influenza. With pandemic threats like H5N1 looming, investing in next-gen antivirals is critical for global preparedness. Library was updated September 2026.





STK093095



STK357174



STK158929

Influenza Targeted Library (INFLUMARK) consists of compounds with potential antiviral activity, which were selected based on similarity to known effectors of proteins, associated with various human Influenza Viruses. This library was designed to provide a potential starting point or to expand ongoing drug discovery project. It is designed in a way that maximizes structur- al diversity and excludes problematic compounds. This library has 5520 compounds. All compounds follow RO5.

Distribution of Parameters



If you have any specific needs for your project, we can provide specially tailored compound library based on your request.

Have questions or need a quote? Contact Irina Haywood (Ryabushenko) at
irina@vitasmlab.biz
Let's Connect on LinkedIn! Expand your professional network.

We look forward to collaborating with you!
Empowering Your Research, One Molecule at a Time.